Physician profile
James Higgins
NPI 1083708697
$3,593.87
in general payments reported to CMS, 2019-2025
24 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,415 · 2020: $443 · 2021: $310 · 2022: $472 · 2023: $773 · 2024: $182.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $954.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $954.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $436.27 | 2019-2023 | Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $421.73 | 2019-2023 | |
| Novo Nordisk INC | $420.51 | 2019-2023 | Wegovy, Ozempic, Rybelsus |
| Janssen Pharmaceuticals, INC | $411.42 | 2019-2023 | Xarelto |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $231.04 | 2019-2024 | Xifaxan, Trulance |
| Lilly USA, LLC | $217.94 | 2019-2023 | Emgality, Jardiance, Mounjaro |
| Astrazeneca Pharmaceuticals Lp | $197.75 | 2019-2020 | |
| Abbott Laboratories | $194.26 | 2022-2024 | Cardiomems, Amplatzer Talisman, Freestyle Libre 3 |
| Allergan, INC. | $187.50 | 2019-2020 | |
| Pfizer INC. | $172.04 | 2019-2023 | |
| Amarin Pharma, INC. | $161.07 | 2019 | |
| Abbvie INC. | $135.14 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $102.61 | 2019-2020 | |
| Abiomed | $68.37 | 2024 | Impella |
| Philips North America LLC | $60.16 | 2023-2024 | (Ck4) Mcot |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $46.72 | 2019 | |
| Shield Therapeutics INC | $32.81 | 2023-2024 | Accrufer |
| Genentech USA, INC. | $18.68 | 2019 | |
| Amgen INC. | $17.86 | 2023 | Otezla, Repatha |
| Exact Sciences Corporation | $14.16 | 2023 | Cologuard Collection Kit |
| Horizon Therapeutics Plc | $13.93 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $13.75 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $11.61 | 2020 | |
| Clarus Therapeutics INC. | $6.54 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Higgins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.